Dr Jimmy Wayne Adams, DO | |
6007 Us Route 60 E, Suite 304, Barboursville, WV 25504-1042 | |
(304) 736-0825 | |
(304) 736-3199 |
Full Name | Dr Jimmy Wayne Adams |
---|---|
Gender | Male |
Speciality | Physical Medicine & Rehabilitation - Pain Medicine |
Location | 6007 Us Route 60 E, Barboursville, West Virginia |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1326128083 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
2081P2900X | Physical Medicine & Rehabilitation - Pain Medicine | 1799 (West Virginia) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Jimmy Wayne Adams, DO Po Box 328, Barboursville, WV 25504-0328 Ph: (304) 736-0825 | Dr Jimmy Wayne Adams, DO 6007 Us Route 60 E, Suite 304, Barboursville, WV 25504-1042 Ph: (304) 736-0825 |
News Archive
Researchers at The Ohio State University are conducting a study to determine which is more effective for helping children on the autism spectrum: training parents or taking medication.
Scientists at the University of Liverpool argue that anti-obesity drugs fail to provide lasting benefits for health and wellbeing because they tackle the biological consequences of obesity, and not the important psychological causes of overconsumption and weight gain.
Testing the saliva of healthy older people for the level of the stress hormone cortisol may help identify individuals who should be screened for problems with thinking skills, according to a study published in the August 19, 2015, online issue of Neurology, the medical journal of the American Academy of Neurology.
Pregnant women exposed to passive smoking are more likely to have sleep disturbances such as subjective insufficient sleep, difficulty in initiating sleep, short sleep duration, and snoring loudly or breathing uncomfortably, according to a study published in the September 1 issue of the journal SLEEP.
ConjuChem, LLC, a biotechnology company dedicated to the discovery of novel therapeutics, today announced it has initiated patient enrollment for its Phase 2 clinical trial of its proprietary GLP-1 receptor agonist drug, CJC-1134-PC, in patients with Type 2 diabetes mellitus who are receiving metformin monotherapy.
› Verified 2 days ago